Hollis-Eden To Testify On Radioprotectant Drug R&D Incentives At House Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
The maker of the radiation therapy Neumune is expected to discuss how federal procurement programs could help stimulate investment in radiation and bioterrorism countermeasures. Hollis-Eden expects to file a Neumune NDA in 2005.